CDK4 and mantle cell lymphoma: For example, the overall response rate (ORR) of Palbociclib, a selective CDK4/6 inhibitor, was 18% in MCL patients [41], while it increased to 21% and 67% after combination with bortezomib [42] and ibrutinib [43], respectively.